Skip to main content
Equibles
AMPH logo

AMPH · Amphastar Pharmaceuticals, Inc. · Webcasts, Transcripts & Audio

Track AMPH — free

Use AMPH with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research AMPH.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$25.30 -0.07 (-0.28%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$1.17B
Shares
42.54M
Volume · Oct 5 454.52K Avg daily vol (3M) 464.78K

Amphastar Pharmaceuticals, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Amphastar Pharmaceuticals, Inc. (AMPH), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲7.1% $120.13M $15.87M '22 Q3 22-11-07 ▲11.7% $135.02M $33.91M '22 Q4 23-02-28 ▲16.3% $140.02M $26.03M '23 Q1 23-05-09 ▲18% $145.71M $26.12M '23 Q2 23-08-08 ▲50.3% $180.56M $49.22M '23 Q3 23-11-08 ▲31.9% $178.10M $36.17M '23 Q4 24-02-28 ▲22.7% $171.84M $43.18M '24 Q1 24-05-08 ▲25.2% $182.39M $37.95M '24 Q2 24-08-07 ▲5.9% $191.21M $40.43M '24 Q3 24-11-06 ▲4.7% $186.52M $37.96M '24 Q4 25-02-27 ▼0.8% $170.53M $25.29M '25 Q1 25-05-07 ▼4.4% $174.41M $31.03M '25 Q2 25-08-07 ▲0.3% $191.84M $17.35M '25 Q3 25-11-06 ▼1.8% $183.10M $24.43M '25 Q4 26-02-26 ▲0.4% $171.17M $6.42M '26 Q1 26-05-07 LATEST ▲5.4% $183.90M $30.35M '26 Q2 26-08-06
Earnings call
FY26 · Q2
2026-08-06
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2026 Earnings Call
Revenue
$183.90M
▲ 5.4% YoY
Diluted EPS
$0.67
▲ 4.7% YoY
Gross margin
50.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Amphastar Pharmaceuticals, Inc. (AMPH) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2026 Earnings Call Transcript
Positive tone BAQSIMI / glucagon pricing pressure Primatene MIST branded growth Full-year 2026 guidance
Revenue
$171.17M
▲ 0.4% YoY
Diluted EPS
$0.14
▼ 72.5% YoY
Gross margin
41.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-02-26
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2025 Earnings Call Transcript
Positive tone Legacy product headwinds Capital allocation (buybacks and business development) BAQSIMI franchise performance and outlook
Revenue
$183.10M*
▼ 1.8% YoY
Gross margin
46.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2025 Earnings Call Transcript
Confident tone BAQSIMI growth and ready-to-use glucagon market Pipeline expansion via Nanjing Anji in-licensing Margin pressure and cost control
Revenue
$191.84M
▲ 0.3% YoY
Diluted EPS
$0.37
▼ 52.6% YoY
Gross margin
51.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2025 Earnings Call Transcript
Positive tone Legacy product pricing pressure and competition BAQSIMI commercial momentum Pipeline and regulatory milestones
Revenue
$174.41M
▼ 4.4% YoY
Diluted EPS
$0.64
▼ 12.3% YoY
Gross margin
49.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-07
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2025 Earnings Call Transcript
Balanced tone BAQSIMI growth and MannKind partnership Glucagon and Epinephrine competitive pressure Tariffs and domestic manufacturing
Revenue
$170.53M
▼ 0.8% YoY
Diluted EPS
$0.51
▼ 37% YoY
Gross margin
50.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2024 Earnings Call Transcript
Positive tone BAQSIMI growth and MannKind partnership Pipeline and GDUFA approvals Primatene MIST branded growth
Revenue
$186.52M*
▲ 4.7% YoY
Gross margin
46.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2024 Earnings Call Transcript
Positive tone BAQSIMI franchise and sales force expansion Primatene Mist growth and expansion Glucagon and other product competition / pricing pressure
Revenue
$191.21M
▲ 5.9% YoY
Diluted EPS
$0.78
▼ 14.3% YoY
Gross margin
53.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-07
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2024 Earnings Call
Revenue
$182.39M
▲ 25.2% YoY
Diluted EPS
$0.73
▲ 49% YoY
Gross margin
52.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-08
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2024 Earnings Call Transcript
Confident tone Hospital and Other Product Sales Net Revenue Growth FTC Orange Book Patent Challenge
Revenue
$171.84M
▲ 22.7% YoY
Diluted EPS
$0.81
▲ 62% YoY
Gross margin
52.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript
Positive tone BAQSIMI transition Diabetes portfolio and glucagon Product launches and pipeline
Revenue
$178.10M*
▲ 31.9% YoY
Gross margin
54.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2023 Earnings Call Transcript
Revenue
$180.56M
▲ 50.3% YoY
Diluted EPS
$0.91
▲ 203.3% YoY
Gross margin
60.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2023 Earnings Call Transcript
Revenue
$145.71M
▲ 18% YoY
Diluted EPS
$0.49
▲ 48.5% YoY
Gross margin
49.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2023 Earnings Call Transcript
Revenue
$140.02M
▲ 16.3% YoY
Diluted EPS
$0.50
▲ 6.4% YoY
Gross margin
52.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-28
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2022 Earnings Call Transcript
Revenue
$135.02M*
▲ 11.7% YoY
Gross margin
52.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2022 Earnings Call Transcript
Revenue
$120.13M
▲ 7.1% YoY
Diluted EPS
$0.30
▼ 49.2% YoY
Gross margin
48.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2022 Earnings Call Transcript
Revenue
$123.47M
▲ 21.4% YoY
Diluted EPS
$0.33
▲ 106.2% YoY
Gross margin
51.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2022 Earnings Call Transcript
Revenue
$120.37M
▲ 16.8% YoY
Diluted EPS
$0.47
▲ 370% YoY
Gross margin
46.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2021 Earnings Call Transcript
Revenue
$120.89M*
▲ 26% YoY
Gross margin
46.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-08
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2021 Earnings Call Transcript
Revenue
$112.20M
▲ 34.5% YoY
Diluted EPS
$0.59
▲ 637.5% YoY
Gross margin
45.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2021 Earnings Call Transcript
Revenue
$101.66M
▲ 18.5% YoY
Diluted EPS
$0.16
Gross margin
46.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2021 Earnings Call Transcript
Revenue
$103.02M
▲ 21.6% YoY
Diluted EPS
$0.10
▲ 25% YoY
Gross margin
43.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-15
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2020 Earnings Call Transcript
Revenue
$95.92M*
▲ 15% YoY
Gross margin
38.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-06
Amphastar Pharmaceuticals, Inc. (AMPH) Q3 2020 Earnings Call Transcript
Revenue
$83.43M
▲ 4.1% YoY
Diluted EPS
$0.08
▲ 166.7% YoY
Gross margin
43.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Amphastar Pharmaceuticals, Inc. (AMPH) Q2 2020 Earnings Call Transcript
Revenue
$85.81M
▲ 8.6% YoY
Diluted EPS
$0.00
▼ 100% YoY
Gross margin
38.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Amphastar Pharmaceuticals, Inc. (AMPH) Q1 2020 Earnings Call Transcript
Revenue
$84.69M
▲ 6.1% YoY
Diluted EPS
$0.08
▲ 300% YoY
Gross margin
43.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2019 Earnings Call
Revenue
$83.38M
▼ 7% YoY
Diluted EPS
$-0.02
▼ 150% YoY
Gross margin
40.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 1297184 CUSIP 03209R103 13F (30d) 7 filings 7 filers Visit website Investor relations